Inovio Pharmaceuticals, Inc.
NASDAQ:INOBiotechnology
-$0.01 today
- Market cap
- $116.77M
- Beta
- 1.49
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$0.12
Volume 11.56M
Average 2.73M
INO Net Income
Bottom-line profit after all expenses, interest, and taxes.
Inovio Pharmaceuticals, Inc.NASDAQ: INO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$19.68M, compared with -$19.69M a year earlier. Trailing-twelve-month net income was -$84.93M.
Context
- Net income amounted to 130000.0% of revenue in FY2025, up 80745.7 pp from a year earlier.
- Net income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -$40.79M (+52.0%) for the fiscal year ending Dec 2026, a step up from the +20.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$19.68M-622.8% QoQ
- Last fiscal yearDec 2025
- -$84.95M+20.8% YoY
- LTMMar 2026
- -$84.93M+12.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +0.1% | +9.1% | +9.1 pp |
| 1 year | +20.8% | +52.0% | +31.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (84.95M) USD
- Year-over-year change
- +20.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (84.95M) | +20.8% |
| FY2024 | 2024-12-31 | (107.25M) | +20.6% |
| FY2023 | 2023-12-31 | (135.12M) | +51.7% |
| FY2022 | 2022-12-31 | (279.82M) | +7.9% |
| FY2021 | 2021-12-31 | (303.66M) | — |
Net Income vs competitors
How INO compares with its peers on the latest reported figures
- INO's LTM Mar 2026 net income of -$84.93M is the 6th highest of the 10 companies compared; the peer median is -$70.49M.
- Its year-over-year change of +12.0% is the 6th highest of 10, against a peer median of +14.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $64.61M | +133.9% | — | 52.2% | |
| LTM Mar 2026 | $15.24M | +121.8% | — | 27.8% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | -$21.54M | +14.9% | — | — |
| LTM Mar 2026 | -$46.9M | -164.3% | — | 4088.8% | |
| LTM Mar 2026 | -$70.49M | +17.9% | — | 468.7% | |
| LTM Mar 2026 | -$84.93M | +12.0% | — | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -$106.93M | -82.4% | — | 892.4% |
| LTM Mar 2026 | -$113.28M | +2.6% | — | — | |
| LTM Mar 2026 | -$125.39M | -1.6% | — | 680.8% | |
| LTM Mar 2026 | -$129.91M | +26.1% | — | 2056.8% | |
| Peer median (excluding INO) | -$70.49M | +14.9% | — | 680.8% | |
Competitors are the stored peer set for INO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.77M | 10.26M | 832.01K | 217.76K | 65.34K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.77M | 10.26M | 832.01K | 217.76K | 65.34K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 249.24M | 187.65M | 86.68M | 75.62M | 54.21M |
| Selling, General & Admin | 53.75M | 90.19M | 47.58M | 37M | 32.68M |
| Operating Expenses | 302.99M | 277.84M | 144.77M | 112.62M | 86.89M |
| Depreciation & Amortization | 4.73M | 5.5M | 3.5M | 3.13M | 2.99M |
| EBITDA | (296.56M) | (270.9M) | (130.39M) | (103.95M) | (81.96M) |
| EBITDA Margin | -16709.7% | -2639.8% | -15671.8% | -47735.2% | -125425.9% |
| Operating Income | (301.22M) | (267.57M) | (143.94M) | (112.4M) | (86.82M) |
| Operating Margin | -16972.3% | -2607.4% | -17300.3% | -51616.9% | -132871.3% |
| Interest Income | 3.36M | 4.78M | 8.13M | 4.77M | 2.42M |
| Interest Expense | 1.94M | 1.25M | 1.22M | 177.83K | 0 |
| Other Income / Expenses | (2.44M) | (12.24M) | 8.82M | 5.14M | 1.88M |
| Income Before Tax | (303.66M) | (279.82M) | (135.12M) | (107.25M) | (84.95M) |
| Pre-Tax Margin | -17109.9% | -2726.7% | -16239.9% | -49254.3% | -130000.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (303.66M) | (279.82M) | (135.12M) | (107.25M) | (84.95M) |
| Net Margin | -17109.9% | -2726.7% | -16239.9% | -49254.3% | -130000.0% |
| EPS (Basic) | (1.42) | (14.07) | (6.09) | (3.95) | (1.81) |
| EPS (Diluted) | (1.42) | (14.07) | (6.09) | (3.95) | (1.81) |
| Weighted Avg Shares | 214.62M | 19.89M | 22.17M | 27.16M | 468.86M |
| Weighted Avg Shares (Diluted) | 214.62M | 19.89M | 22.17M | 27.16M | 468.86M |
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
Intrinsic Alpha fair value
Locked
Current Price
$1.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.